Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire Human Genetic Therapies (Shire) has entered into a research agreement to demonstrate biOasis Technologies' Transcend technology in the area of lysosomal storage disorders (LSDs).
Subscribe to our email newsletter
LSDs which are inherited metabolic disorders can be treated with an enzyme replacement therapy (ERT).
biOasis and Shire’s scientists will jointly collaborate to evaluate the potential of Transcend to deliver an enzyme to the brain, as per the agreement,
As part of the mutual agreements, with their own expenses, biOasis and Shire are conducting certain experiments and Shire has been awarded license to biOasis’ Transcend technology.
biOasis Rob Hutchison CEO said the work will start immediately and over the coming months they are looking forward to work with Shire to successfully achieve the objectives set out in the research work plan.